Posters
Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
03 Nov 2023
ALK-positive lung adenocarcinomas are associated with a younger age at sequencing, lower tumor mutational burden, higher PD-L1 expression, and lower cancer testis antigen burden compared to ALK-wild-type, EGFR mutated, and KRAS mutated lung adenocarcinomas. Our results suggest a need for considering patients with ALK-positive lung adenocarcinomas in clinical trials involving immune checkpoint inhibitors despite their exclusion in many trials.
- Kyle C. Strickland
- Zachary D. Wallen
- Sarabjot Pabla
- Heidi C. Ko
- Mary K. Nesline
- Rebecca A. Previs
- Shengle Zhang
- Jeffrey M. Conroy
- Pratheesh Sathyan
- Kamal S. Saini
- Taylor J. Jensen
- Brian Caveney
- Marcia Eisenberg
- Prasanth Reddy
- Eric A. Severson
- Shakti Ramkissoon